GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Net Cash per Share

BLAC (Bellevue Life Sciences Acquisition) Net Cash per Share : $-1.48 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Bellevue Life Sciences Acquisition's Net Cash per Share for the quarter that ended in Sep. 2024 was $-1.48.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's Net Cash per Share or its related term are showing as below:

BLAC's Price-to-Net-Cash is not ranked *
in the Diversified Financial Services industry.
Industry Median: 1.19
* Ranked among companies with meaningful Price-to-Net-Cash only.

Bellevue Life Sciences Acquisition Net Cash per Share Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Net Cash per Share Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Cash per Share
- -0.09 -0.13 -0.73

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.73 -0.86 -1.33 -1.48

Competitive Comparison of Bellevue Life Sciences Acquisition's Net Cash per Share

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellevue Life Sciences Acquisition's Price-to-Net-Cash Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's Price-to-Net-Cash falls into.


;
;

Bellevue Life Sciences Acquisition Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Bellevue Life Sciences Acquisition's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.015-4.108-0)/5.623
=-0.73

Bellevue Life Sciences Acquisition's Net Cash per Share for the quarter that ended in Sep. 2024 is calculated as

Net Cash per Share (Q: Sep. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.012-6.011-0)/4.041
=-1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellevue Life Sciences Acquisition  (NAS:BLAC) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Bellevue Life Sciences Acquisition Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004